Sentences with word «erlotinib»

A total of 27 % of docetaxel patients had grade 3 or 4 neutropenia, and 29 % had alopecia of any grade; 14 % of erlotinib patients suffered grade 3 or 4 dermatological toxicities.

Mouse studies then confirmed that using the diuretic alongside the cancer drug erlotinib reversed resistance to the drug, and enabled it to kill lung cancer cells.

Mutated KRAS status was present in 22.7 % of docetaxel patients and 23.9 % of erlotinib patients.

For example, epidermal growth factor (EGFR) mutations may result in sensitivity to drugs that are EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib, whereas individuals with the EGFR T790M mutation are more resistant to these drugs.

Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer.

But until now scientists only partially understood how this second mutation allowed the cancer cells to protect themselves against erlotinib.

The team studied a lung cancer drug called erlotinib which can be used to treat between 10 and 30 per cent of lung cancer patients.

The clinician prescribed erlotinib, an EGFR inhibitor, but unfortunately the patient did not respond.

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.

[21] In the recently presented FLAURA study, in which osimertinib was used in untreated patients with advanced EGFR - mutant NSCLC, the HR for systemic disease control and CNS control similarly favored osimertinib over erlotinib or gefitinib, supporting the preclinical data that showed osimertinib's penetration across the BBB and providing support for using this agent in first - line management of EGFR - mutant patients with brain metastases.

Angélica Nogueira - Rodrigues, MD, PhD, of the Brazilian National Cancer Insitute, and her colleagues designed a phase 2 clinical trial to test the potential of the EFGR inhibitor erlotinib combined with chemoradiation therapy in 36 women with cervical cancer.

And rats chose to drink less booze after taking erlotinib (Cell, DOI: 10.1016 / j.cell.2009.03.020).

Although alternative drugs are available once erlotinib stops working, these are much more expensive — and they can also stop working due to cancer cells developing resistance.

Previous studies have found that, in at least half of cases, the cancer cells become resistant to erlotinib by developing a second mutation.

In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine - based induction chemotherapy, and assessed the effect of erlotinib on survival.

Niclosamide may work as therapeutic for familial adenomatosis polyposis (FAP) by disrupting the axin - GSK3 interaction and for colon cancer in synergizing with erlotinib [52,53].

The overall survival was similar between the VS - G patients: 10.92 months in VS - G chemotherapy patients and 10.95 months in VS - G erlotinib patients.

[27,28] In an unselected phase II study, concomitant whole - brain radiation therapy (WBRT) and standard - dose erlotinib were well tolerated, with an ORR of 86 %.

[29] The Radiation Therapy Oncology Group study 0320 evaluated WBRT + stereotactic radiosurgery (SRS) + erlotinib and found significant grade 3 — 5 toxicity rates of 49 %, compared with a rate of 11 % for WBRT alone; the toxicities observed included cytopenias, rash, fatigue, and dehydration, among others.

Unfortunately, it had recently been shown that tumors lacking PTEN and TP53 don't respond to TK inhibitors like erlotinib.

The HR for progression for docetaxel vs. erlotinib was 0.70 (P =.019).

If such an indel is found in this gene, Ding and her colleagues suggest a patient may benefit from an EFGR inhibitor, such as erlotinib, regardless of the tumor type.

Professor Michael Seckl, lead author from the Department of Surgery and Cancer at Imperial said: «Although these are very early - stage results, and are yet to be applied to patients in trials, they suggest the addition of a very cheap diuretic may extend the amount of time we can use the cancer drug erlotinib.

A third approved treatment is an epidermal growth factor (EGFR) inhibitor, called erlotinib.

Patients found to have this mutation are prescribed erlotinib, which blocks this mutated receptor and halts cell growth.

The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer.

A total of 28.9 % of patients receiving docetaxel had not progressed after 6 months, compared with 16.9 % of erlotinib patients.

Dr. Gregorc concluded that patients stratified as VS - P, which will make up about 30 % to 35 % of patients, have better survival with chemotherapy than with erlotinib.

Sure enough, when the team gave the drugs erlotinib and gefitinib to flies, they were more likely to be knocked out by alcohol.

The drug erlotinib is prescribed to between 10 — 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.

The team found that if they raised glutathione levels in cancer cells in the lab, they reversed resistance to the drug erlotinib, and the treatment was once again able to kill cancer cells.

Maintenance chemotherapy was left to the discretion of the treating medical oncologists and consisted of pemetrexed, docetaxel, erlotinib or gemcitabine.

June - Koo Lee, M.D., of Seoul National University Hospital, Seoul, Republic of Korea, and colleagues performed a meta - analysis of randomized controlled trials that compared first - generation EGFR TKI (erlotinib and gefitinib) treatment with conventional chemotherapy in patients with advanced NSCLC without mutation of the EGFR gene.

This study is also important because it explains why some new mutations in EGFR — which are acquired during the course of treatment of lung cancer with small molecule EGFR inhibitors such as erlotinib — lead to drug resistance and patient death.

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer.

Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.

It's been an important question — many lung cancers depend on over-activation of the gene EGFR, but then when EGFR inhibitors like gefitinib or erlotinib are used, the cancers tend to activate other «kinases» that allow the cancer to by - pass around this dependence.

They also analysed the patients» cancers for mutations in two other molecules, one called EGFR which is the target of existing drugs gefitinib and erlotinib, and another called KRAS.

Also, there was no significant difference in overall survival with gemcitabine (13.6 months) compared with gemcitabine plus erlotinib (11.9 months).

Gemcitabine and erlotinib are drugs used to treat cancer.

Since the initial discovery of EGFR mutations in lung cancer 10 years ago, EGFR targeted therapies such as erlotinib (Tarceva) and afatinib (Gilotrif) have become a fundamental component of lung cancer therapy.

For this study, the researchers first randomly assigned 449 patients to receive gemcitabine alone (n = 223) and 219 patients received gemcitabine plus erlotinib.

In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of erlotinib is unknown.

Researchers and physicians have shown success treating EGFR lung cancer, for example with EGFR inhibitors gefitinib and erlotinib.

Kinases are also druggable targets, as seen by the success of kinase - inhibitors in earning FDA approval (including, for example, crizotinib against ALK - fusion and erlotinib against EGFR).

Drugs such as gefitinib and erlotinib are supposed to block those growth signals in lung cancer cells, but not every cancer responds to them.

The median overall survival was 9 months in the entire chemotherapy group and 7.7 months in the erlotinib group, for a hazard ratio of 1.14 (95 % CI, 0.88 — 1.49; P = 0.313).

EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib.

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy - refractory, advanced colorectal cancer.